These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25906645)

  • 1. [Peroxysome proliferator-activated receptors at pathogenesis and treatment of atherosclerosis (achievements, paradoxes and perspectives)].
    Rasin MS
    Lik Sprava; 2014; (5-6):26-38. PubMed ID: 25906645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
    Jay MA; Ren J
    Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.
    Pourcet B; Fruchart JC; Staels B; Glineur C
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):379-401. PubMed ID: 16939380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
    Kuusisto J; Andrulionyte L; Laakso M
    Curr Atheroscler Rep; 2007 Oct; 9(4):274-80. PubMed ID: 18173954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
    Filip-Ciubotaru F; Manciuc C; Grigore C; Foia L
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):240-7. PubMed ID: 23077903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.
    Azhar S
    Future Cardiol; 2010 Sep; 6(5):657-91. PubMed ID: 20932114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
    Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
    J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.
    Khuchua Z; Glukhov AI; Strauss AW; Javadov S
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.
    Robinson E; Grieve DJ
    Pharmacol Ther; 2009 Jun; 122(3):246-63. PubMed ID: 19318113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
    Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptors and atherosclerosis.
    Soskić SS; Dobutović BD; Sudar EM; Obradović MM; Nikolić DM; Zarić BL; Stojanović SD; Stokić EJ; Mikhailidis DP; Isenović ER
    Angiology; 2011 Oct; 62(7):523-34. PubMed ID: 21467121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J
    J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.